This post-hoc analysis compared efficacy of savolitinib plus osimertinib and change in EGFR ctDNA in advanced EGFR-mutant NSCLC characterized by MET amplification.
The definition of hyperprogressive disease (HPD) in advanced non–small cell lung cancer was found to vary widely, yielding “highly variable” rates of HPD.
The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
The drug did, however, significantly improve progression-free survival.
Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.
In the 3 ongoing responses, all had PD-L1–positive disease.
Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.
Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
The OCM Model requires that participating oncology practices collect and report data related to predictive biomarker testing for their patients with advanced NSCLC.
The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Researchers surveyed consecutive new patients at a multidisciplinary clinic to determine smokers’ willingness to participate in a cessation program.
Low-dose erlotinib may be a safe and effective option for frail or elderly patients with EGFR mutation-positive NSCLC.
NSCLC patients who have an ALK rearrangement may have an increased risk for venous thromboembolism and arterial thrombosis, a retrospective cohort study found.
The phase 3 ADAURA trial included 682 patients with EGFR-mutated NSCLC who had complete resection of the disease.
A presentation on the interim results of the phase 3 CheckMate 9LA trial revealed a new first line treatment opportunity for patients with advanced NSCLC.
Results of TERAVOLT showed that chemotherapy alone or in combination was significantly associated with increased risk of death for those with thoracic cancer and COVID-19.
The VA NPOP is a program established to provide access to next-generation sequencing for veterans with advanced solid tumors.